Stock listing
NASDAQ:VRAX Virax Biolabs Group Limited Stock
Home listing (NASDAQ) of Virax Biolabs Group Limited
Follow Virax Biolabs Group Limited into a list and get an email when it puts out news.
Share price · NASDAQ:VRAX
$0.332 USD -0.049 (-12.9%)
Close on Nov 20, 2026
- Day range
- $0.327 – $0.370 USDNov 20, 2026
- Volume
- 85,897 sharesNov 20, 2026
- Market cap
- $446,402 USDAt the close on Nov 20, 2026 · price × 1.34M shares outstanding
- 52-week range
- $0.293 – $21.750 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $510,091 USDMedian day 39,950 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:VRAX · Home | $0.332 USD | -0.049 (-12.9%) | 85,897 | $0.370 | $0.370 | $0.327 | $0.381 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VRAX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.332 | -0.049 | -12.9% | $0.370 | $0.370 | $0.327 | 85,897 | |
| $0.381 | -0.049 | -11.4% | $0.436 | $0.460 | $0.293 | 257,162 | |
| $0.430 | -0.015 | -3.4% | $0.448 | $0.495 | $0.410 | 376,790 | |
| $0.445 | -0.003 | -0.6% | $0.435 | $0.470 | $0.410 | 128,524 | |
| $0.448 | -0.165 | -26.9% | $0.510 | $0.550 | $0.400 | 182,622 | |
| $0.613 | -0.055 | -8.2% | $0.667 | $0.685 | $0.601 | 124,100 | |
| $0.668 | +0.041 | +6.5% | $0.627 | $0.696 | $0.600 | 80,300 | |
| $0.627 | -0.017 | -2.6% | $0.625 | $0.670 | $0.550 | 225,700 | |
| $0.644 | -0.066 | -9.3% | $0.630 | $0.700 | $0.503 | 256,800 | |
| $0.710 | -0.082 | -10.4% | $0.810 | $0.810 | $0.646 | 344,500 | |
| $0.792 | -0.388 | -32.9% | $0.970 | $0.990 | $0.630 | 1,094,700 | |
| $1.180 | -0.020 | -1.7% | $1.330 | $1.349 | $1.010 | 3,710,600 | |
| $1.200 | +0.140 | +13.2% | $1.160 | $1.570 | $1.110 | 10,978,300 | |
| $1.060 | -0.040 | -3.6% | $1.090 | $1.175 | $1.040 | 33,700 | |
| $1.100 | -0.110 | -9.1% | $1.170 | $1.180 | $1.100 | 24,200 | |
| $1.210 | -0.110 | -8.3% | $1.285 | $1.300 | $1.180 | 23,600 | |
| $1.320 | +0.120 | +10.0% | $1.300 | $1.330 | $1.235 | 57,900 | |
| $1.200 | +0.010 | +0.8% | $1.170 | $1.210 | $1.160 | 10,100 | |
| $1.190 | 0.000 | 0.0% | $1.230 | $1.230 | $1.140 | 11,900 | |
| $1.190 | -0.030 | -2.5% | $1.260 | $1.260 | $1.180 | 10,500 | |
| $1.220 | -0.015 | -1.2% | $1.240 | $1.265 | $1.200 | 33,900 | |
| $1.235 | -0.105 | -7.8% | $1.290 | $1.390 | $1.150 | 38,100 | |
| $1.340 | -0.030 | -2.2% | $1.420 | $1.490 | $1.320 | 14,700 | |
| $1.370 | -0.030 | -2.1% | $1.500 | $1.500 | $1.350 | 13,700 | |
| $1.400 | -0.050 | -3.4% | $1.500 | $1.648 | $1.380 | 12,100 | |
| $1.450 | -0.170 | -10.5% | $1.620 | $1.640 | $1.380 | 40,600 | |
| $1.620 | -0.030 | -1.8% | $1.660 | $1.760 | $1.550 | 44,200 | |
| $1.650 | -0.088 | -5.1% | $1.770 | $1.780 | $1.610 | 38,700 | |
| $1.738 | -0.112 | -6.1% | $1.800 | $1.860 | $1.720 | 39,700 | |
| $1.850 | -0.020 | -1.1% | $1.810 | $1.900 | $1.780 | 71,000 | |
| $1.870 | -0.120 | -6.0% | $1.920 | $1.940 | $1.810 | 87,600 | |
| $1.990 | -0.120 | -5.7% | $2.130 | $2.130 | $1.930 | 50,800 | |
| $2.110 | +0.080 | +3.9% | $2.020 | $2.180 | $1.830 | 271,500 | |
| $2.030 | -0.370 | -15.4% | $2.330 | $2.330 | $1.830 | 310,500 | |
| $2.400 | +0.200 | +9.1% | $2.530 | $3.340 | $2.160 | 2,895,100 | |
| $2.200 | -0.040 | -1.8% | $2.210 | $2.250 | $2.130 | 19,600 | |
| $2.240 | +0.056 | +2.6% | $2.180 | $2.374 | $2.180 | 30,800 | |
| $2.184 | -0.046 | -2.1% | $2.250 | $2.270 | $2.130 | 19,500 | |
| $2.230 | -0.084 | -3.6% | $2.270 | $2.395 | $2.040 | 94,000 | |
| $2.314 | -0.081 | -3.4% | $2.350 | $2.350 | $2.300 | 5,500 | |
| $2.395 | -0.045 | -1.8% | $2.380 | $2.600 | $2.380 | 13,400 | |
| $2.440 | -0.110 | -4.3% | $2.277 | $2.470 | $2.277 | 20,600 | |
| $2.550 | +0.050 | +2.0% | $2.520 | $2.600 | $2.500 | 14,300 | |
| $2.500 | +0.190 | +8.2% | $2.380 | $2.650 | $2.285 | 51,000 | |
| $2.310 | -0.230 | -9.1% | $2.480 | $2.540 | $2.145 | 70,800 | |
| $2.540 | +0.010 | +0.4% | $2.500 | $2.580 | $2.490 | 14,600 | |
| $2.530 | +0.040 | +1.6% | $2.530 | $2.600 | $2.500 | 16,500 | |
| $2.490 | -0.100 | -3.9% | $2.590 | $2.590 | $2.450 | 23,800 | |
| $2.590 | -0.020 | -0.8% | $2.660 | $2.775 | $2.580 | 24,400 | |
| $2.610 | -0.060 | -2.2% | $2.590 | $2.750 | $2.580 | 28,900 | |
| $2.670 | -0.180 | -6.3% | $2.770 | $2.840 | $2.600 | 36,900 | |
| $2.850 | +0.120 | +4.4% | $2.730 | $2.920 | $2.700 | 72,000 | |
| $2.730 | +0.100 | +3.8% | $2.660 | $2.760 | $2.630 | 38,300 | |
| $2.630 | +0.005 | +0.2% | $2.600 | $2.660 | $2.560 | 29,000 | |
| $2.625 | +0.065 | +2.5% | $2.540 | $2.635 | $2.540 | 21,800 | |
| $2.560 | +0.015 | +0.6% | $2.625 | $2.690 | $2.520 | 40,200 | |
| $2.545 | -0.055 | -2.1% | $2.560 | $2.610 | $2.540 | 24,400 | |
| $2.600 | -0.220 | -7.8% | $2.820 | $2.835 | $2.560 | 86,200 | |
| $2.820 | 0.000 | 0.0% | $2.920 | $2.920 | $2.770 | 16,800 | |
| $2.820 | -0.120 | -4.1% | $2.890 | $2.945 | $2.750 | 36,600 | |
| $2.940 | +0.170 | +6.1% | $2.800 | $2.950 | $2.720 | 44,200 | |
| $2.770 | -0.140 | -4.8% | $2.870 | $2.940 | $2.730 | 91,500 | |
| $2.910 | -0.090 | -3.0% | $3.000 | $3.000 | $2.900 | 35,900 | |
| $3.000 | -0.190 | -6.0% | $3.140 | $3.190 | $2.900 | 80,900 | |
| $3.190 | -0.260 | -7.5% | $3.510 | $3.510 | $3.140 | 119,000 | |
| $3.450 | +0.270 | +8.5% | $3.200 | $3.640 | $3.100 | 499,000 |
Splits
2 splits since 2023 · NASDAQ:VRAX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:VRAX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 29, 2026
Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 15 slides
Latest news
Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China
Oct 29, 2026
Closed $1.32 (+10.0%) on Oct 29, 2026
Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Jul 20, 2026
Closed $3.89 (+2.6%) on Jul 20, 2026
Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
Jul 16, 2026
Closed $3.90 (+13.0%) on Jul 16, 2026
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
Jul 10, 2026
Closed $4.07 (-0.2%) on Jul 13, 2026
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
Jul 9, 2026
Closed $6.36 (+100.0%) on Jul 9, 2026
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
Jul 9, 2026
Closed $6.36 (+100.0%) on Jul 9, 2026
Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
Jun 24, 2026
Closed $3.30 (-14.8%) on Jun 24, 2026
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
May 26, 2026
Closed $5.68 (-18.3%) on May 26, 2026
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
Mar 31, 2026
Closed $5.50 (+35.0%) on Mar 31, 2026
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
Dec 4, 2025
Closed $15.75 (-2.2%) on Dec 5, 2025
Virax Biolabs Group Limited on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 12 in the last 12 months · 46 in all · newest Oct 29, 2026 · oldest 2022
- Decks
- 4 decks · latest November 2026
Where Virax Biolabs Group Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:VRAX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:VRAX | BOATS | United States | USD |
Valuation
EV/sales −455× against a median of 2.1×: the lowest of 9 Diagnostics & research services companies shown. Statements: Year to Mar 31, 2026 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$5.66M USD
- P/E
- Loss
- EV/sales
- −455×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.1×
- Gross margin
- 61.9%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.38
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Virax Biolabs Group Limited · NASDAQ:VRAX | US$446,402 | −US$5.66M | n/a | −455× | n/a | 0.1× | n/a | 0.1× | 1.38 |
| Innovotech Inc. · TSXV:IOT | US$2.66M | US$2.51M | n/a | 1.0× | n/a | 1.5× | −21.1% | 0.1× | 0.39 |
| Qlife Holding AB · OMXSTO:QLIFE | US$2.49M | US$2.88M | n/a | 34.1× | n/a | 9.6× | n/a | 3.1× | n/a |
| Physiomics PLC · LSE:PYC | US$2.46M | US$1.91M | n/a | 1.6× | n/a | 3.6× | −74.1% | 0.0× | n/a |
| 20/20 BioLabs, Inc. · NASDAQ:AIDX | US$2.10M | −US$1.01M | n/a | −0.5× | n/a | 3.4× | −317.8% | 0.9× | 1.41 |
| Bluejay Diagnostics, Inc. · NASDAQ:BJDX | US$1.90M | −US$5.43M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.71 |
| Accustem Sciences Inc · OTC:ACUT | US$1.90M | US$1.88M | n/a | n/a | n/a | n/a | n/a | n/a | 0.19 |
| InVitro International · OTC:IVRO | US$1.87M | US$644,260 | 29.6× | 0.8× | 14.0× | 1.1× | 8.2% | 0.0× | 0.17 |
| Co-Diagnostics, Inc. · NASDAQ:CODX | US$1.36M | US$2.21M | n/a | 2.6× | n/a | 0.1× | n/a | 0.2× | 2.16 |
| Prostatype Genomics AB · OMXSTO:PROGEN | US$1.36M | US$1.32M | n/a | 13.3× | n/a | 2.1× | n/a | 0.0× | n/a |
| Oxurion NV · EURONEXT:OXUR | US$254,615 | US$12.85M | n/a | 21.1× | n/a | n/a | −671.7% | n/a | n/a |
| Median of the others | US$1.90M | US$1.90M | 29.6× | 2.1× | 14.0× | 1.8× | −74.1% | 0.0× | 0.90 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 25.00 USD · Analysts' mean
- EPS, year to Mar 2027
- -6.00 · 1 analyst
- Revenue, year to Mar 2027
- 4K · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| James Foster | Chairman and Chief Executive Officer |
Board
| Director | Role |
|---|---|
| James Foster | Chairman and Chief Executive Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Dec 2, 2025 | +76.0% |
| Q1 2026 | Jul 2, 2025 | +1.2% |
| Q2 2025 | Nov 20, 2024 | +1.0% |
| Q1 2023 | Jul 21, 2022 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 15 slides | November 2026 |
| Investor Presentation (September 2026) | Investor deck | 20 slides | September 2026 |
| Investor Presentation (April 2026) | Investor deck | 16 slides | April 2026 |
| IPO Roadshow (July 2022) | IPO roadshow | 23 slides | Jul 1, 2022 |
Financings
| Raise | Date |
|---|---|
| Ordinary shares on exercise of preferred investment options Closed: US$3.3M in the latest tranche · US$6 a share · Warrants at US$6 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital for general corporate purposes | Jul 16, 2026 |
| Private placement of ordinary shares (or pre-funded warrants) and preferred investment options Closed: US$5M raised · US$0.3999 a share · Warrants at US$0.4 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: General working capital, extending cash runway into the first half of 2028 | Dec 4, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$5.00 a share on Jul 20, 2022.
- Price
- US$5.00 a share
- Shares offered
- 3,294,784 ordinary shares · 1,350,000 from the company and 1,944,784 from selling shareholders
- Offering size
- US$6.8 million
- Listing
- VRAX on the Nasdaq Capital Market
- Underwriters
- BOUSTEAD SECURITIES, LLC, VALUABLE CAPITAL LIMITED · In the order on the cover
- Shares delivered
- On or about Jul 25, 2022
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 27, 2021 |
| Filed publicly | Mar 18, 2022 |
| Amended 6 times | Newest Jun 27, 2022 |
| Shares registered with an exchange | Jun 30, 2022 |
| Declared effective by the SEC | Jun 30, 2022 |
| Final prospectus, with the price | Jul 21, 2022 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 21, 2022 |
| CERT · Exchange's certificate of listing | Jul 20, 2022 |
| FWP · Free writing prospectus | Jul 1, 2022 |
| EFFECT · Notice that a registration is effective | Jun 30, 2022 |
| FWP · Free writing prospectus | Jun 30, 2022 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 30, 2022 |
| CORRESP · Letter to the SEC | Jun 28, 2022 |
| CORRESP · Letter to the SEC | Jun 28, 2022 |
| F-1/A · Registration statement, amended | Jun 27, 2022 |
| CORRESP · Letter to the SEC | Jun 24, 2022 |
All 31 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Jun 24, 2022 |
| CORRESP · Letter to the SEC | Jun 24, 2022 |
| F-1/A · Registration statement, amended | Jun 24, 2022 |
| UPLOAD · Letter from the SEC | Jun 23, 2022 |
| CORRESP · Letter to the SEC | Jun 21, 2022 |
| F-1/A · Registration statement, amended | Jun 21, 2022 |
| UPLOAD · Letter from the SEC | Jun 16, 2022 |
| F-1/A · Registration statement, amended | Jun 7, 2022 |
| CORRESP · Letter to the SEC | May 11, 2022 |
| F-1/A · Registration statement, amended | May 11, 2022 |
| UPLOAD · Letter from the SEC | May 5, 2022 |
| F-1/A · Registration statement, amended | Apr 25, 2022 |
| CORRESP · Letter to the SEC | Apr 22, 2022 |
| UPLOAD · Letter from the SEC | Apr 7, 2022 |
| CORRESP · Letter to the SEC | Mar 18, 2022 |
| F-1 · Registration statement | Mar 18, 2022 |
| UPLOAD · Letter from the SEC | Mar 10, 2022 |
| DRSLTR · Letter to the SEC with a draft | Feb 17, 2022 |
| DRS/A · Draft registration statement, amended | Feb 17, 2022 |
| UPLOAD · Letter from the SEC | Jan 28, 2022 |
| DRS · Draft registration statement | Dec 27, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 21, 2022
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | 12.4K | 6.33K | 156.4K | 8.56K | 0 | 123.8K | 99.9K |
| Cost of revenue | 4.73K | 59.4K | 105.8K | 9.93K | 0 | 133.3K | 54.1K |
| Gross profit | 7.69K | -53.1K | 50.6K | -1.36K | 0 | -9.43K | 45.7K |
| Research and development | 3.74M | 1.78M | 1.56M | 2.18M | 433.7K | 120.2K | 87.0K |
| Selling, general and administrative | 2.67M | 4.33M | 4.59M | 5.31M | 1.29M | 457.7K | 602.3K |
| Operating income | -6.40M | -6.16M | -6.50M | -5.73M | -1.73M | -644.5K | -651.2K |
| Depreciation and amortization | 439.0K | 266.6K | 54.9K | 0 | 0 | 644.5K | 651.2K |
| EBITDA | -5.96M | -5.90M | -6.44M | -5.73M | -1.73M | 0 | 0 |
| Interest expense | 61.8K | 58.2K | 26.9K | 15.5K | 15.4K | 28.6K | 90.7K |
| Income before tax | -5.93M | -6.20M | -6.74M | -5.46M | -1.75M | -672.9K | -739.5K |
| Income tax | -900.2K | -136.7K | -194.5K | -271 | -1.77M | -666.5K | 61.7K |
| Net income | -5.02M | -6.06M | -6.73M | -5.46M | -1.71M | -651.0K | -801.1K |
| Earnings per share, basic | -12.64 | -1.62 | -3.36 | -5.13 | -1.79 | -14.31 | -17.61 |
| Earnings per share, diluted | -1.62 | -3.36 | -5.13 | -1.79 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 6.44M | 4.23M | 3.59M | 9.35M | 21.8K | 17.6K | 22.6K |
| Short-term investments | 79.3K | 94.2K | 77.3K | 49.3K | 6.00K | ||
| Receivables | 30.7K | 217.8K | -24.1K | 0 | 928 | 0 | |
| Inventory | 48.0K | 94.7K | 60.4K | 0 | 21.0K | 21.1K | 0 |
| Current assets | 6.83M | 4.89M | 4.38M | 9.63M | 48.7K | 39.6K | 22.6K |
| Property, plant and equipment | 1.23M | 897.6K | |||||
| Total assets | 8.32M | 6.43M | 5.48M | 9.81M | 48.7K | 39.6K | 22.6K |
| Accounts payable | 51.8K | 56.1K | 45.6K | 159.9K | 846.5K | 217.1K | 212.8K |
| Current liabilities | 685.0K | 673.2K | 168.8K | 908.4K | 1.25M | 871.4K | 1.24M |
| Total debt | 414.4K | 377.0K | 224.3K | 146.3K | 3.76K | 179.5K | 759.4K |
| Total liabilities | 989.8K | 964.8K | 345.2K | 908.4K | 1.25M | 871.4K | 1.24M |
| Shareholders' equity | 7.58M | 5.70M | 5.37M | 9.13M | -974.6K | -650.7K | -1.06M |
| Shares outstanding | 397.6K | 4.34M | 2.57M | 1.55M | 9.98M | 45.5K | 45.5K |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -4.62M | -4.56M | -6.25M | -4.18M | -809.1K | -590.2K | -744.6K |
| Capital spending | -255.8K | -603.9K | -952.5K | -178.4K | 0 | 0 | 0 |
| Free cash flow | -4.88M | -5.17M | -7.20M | -4.36M | -809.1K | -590.2K | -744.6K |
| Cash from investing | -255.8K | -603.9K | -1.16M | -178.4K | -178.4K | -178.4K | -178.4K |
| Cash from financing | 7.09M | 5.81M | 1.65M | 13.7M | 813.2K | 585.2K | 704.6K |
| Change in cash | 2.21M | 639.7K | -5.76M | 9.33M | 4.13K | -4.99K | -40.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 18, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 13, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 29, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Oct 21, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Oct 9, 2026 | Current report | SEC |
| 424B3 · Prospectus | Sep 9, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 4, 2026 | Current report | SEC |
| 424B5 · Prospectus | Sep 4, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 4, 2026 | Other filings | SEC |
| F-3/A · Registration statement, amended | Sep 2, 2026 | Offer document | SEC |
All 161 filings
Cap table
Built by 6ix from Virax Biolabs Group Limited’s releases · as of Jul 16, 2026
- Common shares
- 1,344,988
- Fully diluted
- 1,344,988
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,344,988 |
Warrants and options
| Lot |
|---|
| Warrants · US$6.00 · expiry not stated |
| Warrants · US$0.40 · expire about Dec 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,344,988 |
| Jun 24, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Nelson M Haight Other companies: Mountain Crest Acquisition 6 Corp. (Director · Since at least Apr 29, 2026); Team, Inc. (Chief Financial Officer · Since at least Jun 13, 2022); Key Energy Services Inc (Chief Financial Officer · Jun 15, 2020 – Jun 15, 2020 · Past); Playboy, Inc. (Director · Jun 4, 2020 – Jun 4, 2020 · Past); Amplify Energy Corp. (EVP and CFO · Apr 19, 2012 – Apr 21, 2017 · Past) | Director · Since at least Mar 18, 2026 |
| Jason D. Davis Other companies: FibroBiologics, Inc. (Chief Financial Officer · Since at least Jun 9, 2025); Particle Drilling Technologies Inc (Interim Chief Financial Office · Jan 5, 2009 – Apr 17, 2009 · Past) | Chief Financial Officer · Since at least Mar 18, 2026 |
| Evan Michael Norton | Director · Since at least Mar 18, 2026 |
| Iain David Miller | Director · Since at least Mar 18, 2026 |
| James Foster | Chairman and Chief Executive Officer · Since at least Dec 3, 2025 |
| Nigel William McCracken | Chief Operating Officer, Director · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about Virax Biolabs Group Limited.